Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling

Inclusion criteria: * Patients aged \>18 years and \<90 years * LVEF\<60% and EROA of mitral regurgitation≥0.2cm2 on echocardiography * The structure of mitral valve leaf and chordae tendineae is normal * Patients have received GDMT for FMR including a stable, optimized dose of β-blocker and RAAS inhibitors for at least 2 weeks * No intravenous anti-heart failure drugs used for the past 2 weeks * Written informed consent Exclusion criteria: * Allergic to dapagliflozin, or angioedema * Already taking dapagliflozin or other SGLT2 inhibitors * Presence of primary structural damage to the mitral valve, such as rheumatic heart disease, mitral valve prolapses * Non-dialysis chronic kidney disease (CKD) patients with eGFR \<30ml/min/1.73m2 or dialysis patients * Acute myocardial infarction and acute myocarditis occurred within 3 months * Revascularization procedure, CRT, TMVR, surgical valve repair or replacement were performed or planed 3 months before or after enrollment * Combining significant aortic valve diseases (moderate or severe regurgitation or stenosis) * Combining hyperthyroidism while thyroid function has not returned to normal * Pregnant or lactation women